Livagen (Bioregulator)

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) belonging to the Khavinson class of bioregulatory peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It is designed to target hepatic (liver) tissue through proposed peptide-DNA interactions that modulate gene expression in hepatocytes. Livagen is notable in the bioregulatory peptide literature for being one of the first Khavinson peptides studied for its effects on chromatin condensation. Researchers reported that Livagen could decondense heterochromatin in aging lymphocyte and hepatocyte nuclei, potentially reactivating genes silenced by age-related chromatin compaction. This observation provided some of the early experimental support for the Khavinson hypothesis that short peptides can directly influence chromatin structure and gene accessibility. Livagen has been investigated in models of hepatic aging and liver tissue homeostasis.

Livagen has been investigated for its proposed interactions with chromatin structure and gene regulatory regions in hepatic cells. In the Khavinson bioregulatory model, the Lys-Glu-Asp-Ala sequence is proposed to penetrate cell membranes and interact with DNA in a sequence-specific manner, modulating transcription of liver-expressed genes. Researchers observed that Livagen treatment was associated with heterochromatin decondensation in hepatocyte nuclei from aged animal models, suggesting the peptide may influence chromatin accessibility. Studies from the Saint Petersburg group demonstrated that Livagen treatment in aged lymphocyte cultures was associated with changes in the ratio of euchromatin to heterochromatin, potentially making previously silenced gene regions accessible for transcription. In hepatocyte models, researchers observed changes in expression of genes involved in hepatic metabolism, detoxification, and protein synthesis following Livagen treatment. These effects are attributed to direct peptide-DNA interactions and chromatin remodeling rather than conventional receptor signaling.

Chromatin Remodeling

Lezhava and Khavinson (2004) investigated Livagen’s effects on chromatin condensation in human lymphocytes from elderly donors. Researchers observed heterochromatin decondensation following Livagen treatment, suggesting the peptide influences chromatin structure in aging cells [1].

Bioregulatory Peptide Framework

Khavinson VK (2002) described the comprehensive bioregulatory peptide model including liver-targeted peptides, presenting evidence from preclinical studies on tissue-specific peptide-DNA interactions [2].

Hepatic Gene Expression

Khavinson et al. (2005) investigated short peptides in hepatocyte culture models and observed changes in gene expression profiles related to hepatic function following treatment with liver-targeted bioregulatory peptides [3].